Excogitātor

Don’t be the best.Be the only.

A distinct human presence is becoming scarce.

Veni, vidi, cogitavi

Dr. Shayne Heffernan Ph.D.

Shayne Heffernan

Every financial revolution has changed the speed and the surface of finance without changing its substance. Debt cycles still overshoot. Inflation still compounds. Bubbles still form around the new thing while the old rules keep applying. What is different this time is that intelligence itself has become abundant, and everything abundant gets cheap. The scarce thing now is a distinct human presence: judgement shaped by real consequence, taste built over decades, and the willingness to care about a question for longer than is efficient.

I write about that gap most days, and I build in it the rest of the time. Forty years across capital markets, venture capital and emerging technology, and the part that still cannot be automated is the judgement about which question was worth asking. Everything below is published at Live Trading News, wrapped in post-quantum cryptography and anchored on chain at the moment it goes out. The text cannot be altered. Change a word and it is re-signed and re-stamped, and the chain records the new time, so every version and every date stands permanently on the record.

AI

The build-out, the quantum timeline, and what any of it is actually for.

Thinking

Judgement, independence, and staying non-fungible in an AI world.

Markets

Stocks, macro, ramblings and the KXCO build.

Longevity

Healthspan science, and separating the evidence from the sales pitch.

Life

Food, travel, sport, and the unoptimised parts that refill the well.

Latest

15 November 2026

KXCO's FDA Ontology Ranked INO-3107 First. Its Two Published Books Beat XBI.

KXCO's FDA ontology ranked INO-3107 first before the FDA approved it on 30 October 2026; Inovio (INO) then hit $2.71 after hours from a $0.60 close. KXCO's two published research books on the ontology stood at 109.31 and 110.28 at the close of 13 November, from 100 at the close of 14 October, against 102.58 for XBI. Nine more decisions on the board fall due before 31 December, starting with molgramostim (SVRA) and deramiocel (CAPR) on 22 November.

15 November 2026

AI Is Still a Buy: The Noise Will Not Stop the Build-Out

In my view AI is still a buy. NVIDIA announced on 12 November 2026 that Jensen Huang had resigned as chief executive, and the push against data centres widened, yet four of the largest cloud sellers carry about $2.48 trillion of signed backlog and the build kept moving. NVIDIA closed at $162.85 on 13 November 2026 with an average analyst target 71.71% above the price. KXCO's AI ontology shows the same US companies have announced capacity in the UAE, Saudi Arabia, Japan, Malaysia and India.

13 November 2026

Jensen Huang, Nvidia and the Morality Game America Plays With Itself

Jensen Huang resigned as Nvidia's chief executive on 12 November 2026 after reports of three relationships. Whether a foreign service reached him, and whether ties to staff broke Nvidia's own conflict rules, are questions for investigators and the board. His marriage is not. A third of Americans say they have cheated on a partner or spouse, and US fans spent an estimated $4.9 billion on OnlyFans in a year. The outrage is selective, and it is never aimed at the audience.

11 November 2026

The Nvidia Honeypot: Alice Huang and the China-Linked Network Around Megaspeed

Jensen Huang has admitted an affair with Alice Huang, a former Megaspeed executive whom US intelligence reportedly believes China recruited. Nvidia can still sell a great deal to China legally. The question is whether this relationship got its chips around the export rules. There is no public finding that it did, and Nvidia says its checks found Megaspeed owned outside China. The network around her runs to 7Road, Alibaba's money and a state-controlled bank.

10 November 2026

KXCO's FDA Ontology Ranks Lorundrostat First After Its 10 November Update

KXCO's FDA ontology at kxco.ai/fda was updated in full on 10 November 2026. Its first screen now ranks Mineralys's lorundrostat (MLYS) first of the FDA decisions due within 90 days: decision 22 December, potential return +86%, per the page. Mineralys's shares fell 24.5% between reads on 20 October and 10 November. The update read six quarterly reports to 30 September by hand, and on KXCO's calculation Mineralys is funded to 12 October 2029, even if it repays its $100.0m loan by 30 June 2028.

The full archive on Live Trading News